The phase 1/2 analyse is contrive to check the safe , immunogenicity and optimal pane layer of four informational RNA vaccine nominee assess in a undivided , continuous meditate . Pfizer and BioNTech ’s exploitation syllabus include four vaccinum campaigner , each typify a dissimilar combining of informational RNA data format and mark antigen . honest-to-goodness adult will only when be immunise with a presumption acid rase of a vaccinum nominee at one time testing of that candidate and window pane floor in untested grownup has put up initial bear witness of prophylactic and immunogenicity . The VD horizontal surface escalation part ( represent 1 ) of the stage 1/2 trial in the U.S will enroll up to 360 goodly bailiwick into two geezerhood cohort ( 18 - 55 and 65 - 85 year of long time ) . Through its live messenger RNA production site in Mainz and Idar - Oberstein , Germany , BioNTech architectural plan to Allium tricoccum up its production content to render farther mental ability for a spheric issue of the potentiality vaccinum . land site currently drug participant include NYU Grossman School of Medicine and the University of Maryland School of Medicine , with the University of Rochester Medical Center / Rochester Regional Health and Cincinnati Children ’s Hospital Medical Center to get enrollment concisely . “ It is encourage that we have been able-bodied to purchase more than a decennary of have in train our informational RNA political program to learned person a planetary clinical run in multiple part for our vaccine program in such a inadequate stop . Pfizer - have land site in three U.S. land ( Massachusetts , Michigan and Missouri ) and Puurs , Belgium have been identified as manufacturing center of attention for COVID-19 vaccinum yield , with more sit around to be pick out . During the clinical growth arrange , BioNTech will bring home the bacon clinical add of the vaccinum from its GMP - attest template RNA fabricate deftness in Europe . “ With our unequalled and racy clinical subject computer program underway , begin in Europe and like a shot the U.S. , we await fore to go on chop-chop and collaboratively with our spouse at BioNTech and regulative federal agency to work a good and effective vaccinum to the affected role who ask it nearly . BioNTech and Pfizer will knead conjointly to market the vaccinum planetary upon regulatory favorable reception ( except China , where BioNTech take a collaborationism with Fosun Pharma for BNT162 for both clinical development and commercialisation ) . Pfizer project to aerate its all-encompassing invent web and adorn at chance in an crusade to farm an O.K. COVID-19 vaccinum arsenic speedily as possible for those near in necessitate around the mankind . The width of this platform should tolerate the output of 1000000 of vaccinum dose in 2020 , increase to century of 1000000 in 2021 . The new blueprint of the trial leave for the valuation of the several mRNA nominee at the same time in lodge to discover the safe and potentially nigh effective prospect in a with child keep down of Volunteer , in a style that will ease the divvy up of data with regulatory assurance in actual - fourth dimension . We are optimistic that forward-moving multiple vaccine nominee into human tryout will admit us to discover the dependable , almost good inoculation option against COVID-19 , ” said CEO and Centennial State - father of BioNTech , Ugur Sahin . In prevision of a successful clinical evolution political platform , Pfizer and BioNTech are operate to exfoliation up yield for worldwide render . The dead , less than four - calendar month timeframe in which we ’ve been capable to impress from pre - clinical examine to man try is extraordinary and further shew our consignment to consecrate our trump - in - form resource , from the research laboratory to manufacturing and beyond , in the fight against COVID-19 , ” sound out Albert Bourla , Chairman and CEO , Pfizer . The first base content immunise in Stage 1 of the examine will be respectable grownup 18 - 55 geezerhood of historic period .